Communiqués PolyPid Ltd.

Actions

PYPD

IL0011326795

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 13/08/2026			Varia. 5j.	Varia. 1 janv.
4,780 ^USD	-1,24%		-0,62%	+10,14%

12/08	Transcript : PolyPid Ltd., Q2 2026 Earnings Call, Aug 12, 2026
12/08	PolyPid Ltd. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

12/08	PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results	AQ
30/07	PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100	AQ
30/07	PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026	AQ
29/07	PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀	AQ
21/07	PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada	AQ
01/06	PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀	AQ
20/05	PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference	AQ
13/05	PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results	AQ
06/05	PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026	AQ
28/04	PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting	AQ
13/04	PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026	AQ
31/03	PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA	AQ
17/03	PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application	AQ
25/02	PolyPid Announces Participation in Upcoming Investor Conferences	AQ
11/02	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results	AQ
28/01	PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026	AQ
16/12	PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors	AQ
03/12	PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission	AQ
25/11	PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025	AQ
12/11	PolyPid : Investor Presentation (29305a)	PU
12/11	PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results	AQ
06/11	PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"	AQ
29/10/25	PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025	AQ
14/10/25	An Overlooked Crisis in Hospitals Could Be Pharma's Next Great Opportunity	AQ
30/09/25	PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress	AQ